Please try another search
For the nine months ended 30 September 2021, Odonate Therapeutics Inc revenues was not reported. Net loss decreased 26% to $69.8M. Lower net loss reflects Research and development decrease of 54% to $25.1M (expense), Labor & Related Expenses in R&D decrease of 50% to $12.6M (expense), Stock-based Compensation in R&D decrease of 48% to $3.5M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$3.00 to -$1.85.
| Period Ending: | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | ||||
| Operating Income | -14.02 | -22.05 | -33.82 | -32.43 |
| Net Income | -14 | -22.02 | -33.77 | -32.29 |
| Period Ending: | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|
| Total Assets | 105.77 | 118.57 | 142.88 | 167.89 |
| Total Liabilities | 34.4 | 33.95 | 37.58 | 31.74 |
| Total Equity | 71.37 | 84.62 | 105.3 | 136.15 |
| Period Ending: | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|
| Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
| Cash From Operating Activities | -63.04 | -47.94 | -24.91 | -113.13 |
| Cash From Investing Activities | -0.03 | -0.03 | -0.02 | -0.43 |
| Cash From Financing Activities | 0.82 | 0.82 | 0.82 | 90.37 |
| Net Change in Cash | -62.24 | -47.14 | -24.11 | -23.2 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
